She has been a surgical oncologist since 2008 at Mount Sinai Hospital (MSH) and Princess Margaret Cancer Centre in Toronto, Ontario, Canada where she also has an independent research lab at the Lunenfeld-Tanenbaum Research Institute. Her team has been investigating novel drugs for one of the most common types of sarcoma, undifferentiated pleomorphic sarcoma or UPS. One of the challenges faced by UPS patients is the development of metastatic disease, for which current chemotherapy has limited efficacy. Dr. Gladdy’s lab is part of the Sarcoma Precision Medicine Program at MSH led by Dr. Jay Wunder. In previous work, her team screened over 3300 compounds on patient derived UPS cell lines to identify new drugs. Surprisingly, statins or anti-cholesterol drugs were the top hits of the drugs screened for impairing sarcoma viability.